Cleanspace Holdings Ltd. · ASX:CSX
Cleanspace — Shareholder Meeting (November 2024)
17 slides from Cleanspace's shareholder meeting presentation, Nov 11, 2024
Slide 1: FY24 AGM CEO Presentation
For personal use only FY24 AGM CEO PRESENTATION CLEANSPACE HOLDINGS LIMITED (ASX: CSX) CleanSpace designs and manufactures innovative respiratory protection solutions for industrial & healthcare workers globally We understand the importance of best-in-class personal protective equipment that not onl
Slide 2: Important Notice & Disclaimer
IMPORTANT NOTICE & DISCLAIMER ACCEPTANCE differ from the figures set out in this presentation. This presentation has been prepared by CleanSpace Holdings Limited (ACN 150 214 636) (CleanSpace). PAST PERFORMANCE By accepting, accessing or reviewing this presentation, you acknowledge and agree to the
Slide 3: FY24 - Strong Momentum
FY24 - STRONG MOMENTUM DELIVERING AGAINST OUR OBJECTIVES IN FY24 For personal use only ▪ Substantial progress with Industrial-led growth strategy: ▪ Revenue $15.7M (growth +30% v PCP) ▪ Industrial Revenue growth +35% (to $15.1M from FY22: $8.0M) ▪ Right sizing cost base delivered $4M savings ▪ Fully
Slide 4: FY24 – Delivered on FY24 Objectives
FY24 – DELIVERED ON FY24 OBJECTIVES For personal use only FY24 OBJECTIVES # FY24 DELIVERY • Potential for 30%+ revenue growth ✓ 30% revenue growth* • Gross Margin favourable v FY23 ✓ GM 72% (v 70% in PCP) • Build consumable revenue streams ✓ Consumable growth of 28% • Ongoing cost base optimisation
Slide 5: Trends Are Positive for Outlook
TRENDS ARE POSITIVE FOR OUTLOOK For personal use only POSITIVE KEY METRICS ▪ Expenses H2FY24 -44% v H2FY22 ▪ Industrial revenue +88% (+$7M) v FY22 ▪ GM% increased from 70% -> 72% (v FY23) ▪ EBITDA loss reducing fast ▪ Positive EBITDA in Q4 ▪ Positive EBITDA goal in FY25 $M Prior year legacy impacts
Slide 6: FY24 Results
FY24 RESULTS Sector Revenue: ▪ Industrial 35% growth, highest ever sales INDUSTRIAL REVENUE ▪ FY22 $8.0M -> FY24 $15.1M GROWTH ▪ 96% of total revenue For personal use only 35 % UP ON PCP 72% GROSS MARGIN ▪ Healthcare revenue (-15% v PCP) continues to reflect lower demand post pandemic (in US and Asi
Slide 7: FY25 – Objectives
FY25 – OBJECTIVES For personal use only FY25 OBJECTIVES • 30%+ Revenue growth • EBITDA/Cashflow break-even or better • Strong growth in all Priority Markets • Build consumable revenue streams over the long term • Self-fund investments to drive growth • P&L Leverage via tight cost control • Appoint n
Slide 8: Operational Update – FY25 months to date
OPERATIONAL UPDATE – FY25 4 months to date ▪ Slow start to FY25 trading ▪ Fundamentals and underlying strategy remain sound For personal use only ▪ We are committed to achieving our FY25 objectives ▪ Revenue is ~flat v PCP (4 months to October) ▪ Revenue is ~50% higher than FY23 first 4 months ▪ EU
Slide 9: Operational Update – FY25 months to date
OPERATIONAL UPDATE – FY25 4 months to date For personal use only ▪ Gross Margin +2% v PCP Continuous Improvement initiatives ▪ Opex ~5% lower than PCP Some one off people costs included ▪ EBITDA Small EBITDA loss ~+20% better than PCP ▪ Cash ~$8.5m – FY24 bonus and insurance/one off staff payments R
Slide 10: Strengthening Leadership and Transition
STRENGTHENING LEADERSHIP and TRANSITION For personal use only LEADERSHIP ▪ Paul Cassano appointed as Non-Executive Director September 2023 ▪ Bree Greeff promoted to Permanent CFO from March 2024 ▪ Greg Sesny appointed as RVP North America in August 2024 ▪ CEO Graham McLean to assume Chair role from
Slide 11: Strategy Focus – Accelerate Sales Growth Whilst Containing Cost
STRATEGY FOCUS – ACCELERATE SALES GROWTH WHILST CONTAINING COST For personal use only STRATEGY RECAP As the post pandemic environment became clearer, we have reset our strategy. We will drive sustainable growth with strong foundations and a fitter, leaner organisation by: 1. Focusing on industrial a
Slide 12: Summary
SUMMARY STRATEGY TO DELIVER @ 30% REVENUE GROWTH For personal use only SUSTAINABLE MODEL with P&L LEVERAGE Our Growth Drivers: ✓ Innovative new, premium products & launches ✓ Focus on Industrial sectors ✓ 6 Priority markets ✓ Challenger Brand Costs and Cash management: ✓ Careful management of cash w
Slide 13: Appendix
Appendix For personal use only CLEANSPACETECHNOLOGY.COM CleanSpace Holdings Limited | FY24 AGM Presentation | November 2024
Slide 14: Regional and Sector Sales Analysis
REGIONAL and SECTOR SALES ANALYSIS Revenue H1 FY23 H2 FY23 H1 FY24 H2 FY24 FY24 v PCP FY24 H2 v For personal use only Industrial AUD PCP FY24 v PCP Europe $2.9m $4.2m $4.8m $5.3m +43% +26% +43% Asia Pacific $1.3m $1.4m $1.6m $1.9m +30% +36% +40% North $1.6m $0.7m $0.9m $1.2m -9%* +60% +2% America To
Slide 15: FY24 Income Statement Summary
FY24 INCOME STATEMENT SUMMARY Change (A$m) vs PCP F / U H1 FY24 H2 FY24 FY24 % ▪ Revenue increase 30% v PCP and 16% v H1 For personal use only Revenue 7.3 8.4 15.7 30 F Gross Profit 5.2 6.2 11.4 35 F ▪ Increased high gross margin (72%) +2% v PCP Employment costs (4.7) (4.4) (9.1) 26 F ▪ Operating ex
Slide 16: FY24 Summary Balance Sheet & Cash Flows
FY24 SUMMARY BALANCE SHEET & CASH FLOWS as at as at Summary Balance Sheet (A$m) Summary Cash Flows (A$m) H1 FY24 H2 FY24 FY24 FY23 30 Jun-24 30 Jun-23 For personal use only Cash, cash equivalents and term deposits 9.8 12.2 Operating cash flows pre-financing (2.1) (0.3) (2.4) (7.6) and tax Trade and
Slide 17: For personal use only
For personal use only WWW.CLEANSPACETECHNOLOGY.COM 23 CleanSpace Holdings Limited | FY24 AGM Presentation | November 2024
CleanSpace Holdings — Shareholder Meeting (November 2024) on 6ix